It was good to see SCPH up ~25% on their quarterly update in May. Company still only ~$200M market cap, so plenty of room to run up this year.

Overview: • Under the radar companies • Huge upside • Difficult FDA approval behind them ⇒ Typical for drug device combo ⇒ 2 CRLs • But...

Overview: • One of my favorite under the radar companies • Huge upside • Difficult FDA approval behind them   ⇒ Typical for drug device combo   ⇒ 2 CRLs • But still high risk/high reward stock Details: Single drug company • Furoscix   ⇒ SubQ furosemide via on body infusor   ⇒ Diuretic for fluid build up in chronic heart failure • Early commercial - Launched Feb ‘23 • Market opp $7B Sales Pitch: Large cost savings for Medicare & insurers ✔️Patients stay home instead of IV @ ho

(Posted 9:55am CST) $XBI $79.73 | -1.19% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

(Posted 9:55am CST) $XBI $79.73 | -1.19% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

$XBI $74.27 | -0.71% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #HGEN -4% NIH/NIAID Locks...

$XBI $74.27 | -0.71% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #HGEN -4% NIH/NIAID Locks...

As February begins, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD...

Presentations at 62nd American Society of Hematology Annual Meeting